Sienna Cancer Diagnostics - Current News

Investor Update

Investor Update June 2019
19/06/2019

Update on Sienna Cancer Diagnostics emailed to investors including our latest news & media coverage.

Please do not delete the line above. It is...Read More

ASX:SDX Announcement

Sienna Granted Chinese Patent for SIEN-NET™
22/05/2019

Sienna is pleased to announced the grant of a second patent in China for the liquid biopsy sample preparation technology, SIEN-NET™. 

This newly granted patent protects...Read More

ASX:SDX Announcement

StatLab Implementing Strategies To Increase hTERT Sales In The USA
21/05/2019

Sienna recently conducted a video interview with Wayne Rigler, Executive Vice-President of Sales and Marketing for StatLab. The video provides shareholders with...Read More

ASX:SDX Announcement

Sienna Acquires Unique Liquid Biopsy & Exosome Isolation Technology
02/04/2019


Sienna Acquires Unique Liquid Biopsy & Exosome Isolation Technology

  • Sienna to acquire US-based Sevident...Read More

ASX:SDX Announcement

Sienna Appoints Exclusive Distribution Partner for Brazil
18/03/2019

Inside Diagnósticos appointed as exclusive distributor.

Brazil is a major market with significant opportunity for growth.

Sienna has appointed Read More

ASX:SDX Announcement

FNN coverage - CEO Interview 2019 update
13/03/2019

In this interview, Sienna CEO Matthew Hoskin shares an update on the Company’s progress in 2018, expectations for 2019 and the product expansion strategy.


Read More

Investor Update

Investor Update – March 2019
12/03/2019

Please do not delete this line. It is required for news page to show "read more" correctly.

...Read More

ASX:SDX Announcement

Sienna Furthers its Global Expansion with Distributor for Singapore
04/02/2019
  • Mediwell Enterprise Pte. Ltd (Mediwell) appointed as distribution partner for Singapore.
  • Singapore has a fast-growing market for in-vitro...Read More

ASX:SDX Announcement

Appendix 4C – 31 December 2018 – released to the ASX on 31 January 2019
31/01/2019

Sienna is pleased to release its Appendix 4C – Quarterly Cash Flow Report for the quarter ending 31 December 2018.

Download HereRead More

ASX:SDX Announcement

Appendix 4D and Half-Year Financial Report to 31 Dec 2018 – released to the ASX on 31 January 2019
31/01/2019

Sienna is pleased to release its Appendix 4D and Half-Year Financial Report for the 6 months ending 31 December 2018.

Download HereRead More

ASX:SDX Announcement

Sienna furthers its Global Expansion with Distributor for the Republic of Korea
22/01/2019
  • Mirax Corporation appointed as exclusive distributor for Korea
  • Important expansion of commercial opportunity in high-growth Asian IVD market

Sienna...Read More

Investor Update

Investor Update – September 2018
03/09/2018

Please do not delete this line. It is required for news page to show "read more" correctly.

...Read More

ASX:SDX Announcement

Thyroid Study Initiated at RMH
30/08/2018

Work on expanding the indications for Sienna’s hTERT test has resulted in a new study commencing.

  • Multiple sample types being sourced...Read More

ASX:SDX Announcement

Sienna Appoints Chinese Distributor
07/08/2018
  • GaoYuan In-Vitro Reagents Co. appointed as exclusive distributor for mainland China.
  • China is a fast growing consumer of...Read More

ASX:SDX Announcement

Placement & Rights Issue to Accelerate Technology Expansion Program
20/07/2018

 

  • Sienna to raise a total of $5.2 million via a placement and rights issue
  • Merchant Opportunities Fund and...Read More

ASX:SDX Announcement

Johns Hopkins Study Published in Peer-Reviewed Journal
07/06/2018

Sienna is pleased to announce the results of the largest independent study to date using Sienna’s IVD test, conducted by Johns Hopkins Hospital, have been ...Read More

ASX:SDX Announcement

Sienna Received R&D Tax Incentive Refund
22/05/2018

Sienna is pleased to announce the Company has received its R&D Tax Incentive Refund of $631,691 for the 2017 financial year.

The amount received provides...Read More

ASX:SDX Announcement

Sienna updates Finance News Network (FNN)
15/05/2018

In this interview, Sienna’s CEO Matthew Hoskin speaks to FNN’s Jessica Amir about the Johns Hopkins clinical study results, and the company’s progress ...Read More

Investor Update

Investor Update May 2018
09/05/2018

Please do not delete this line. It is required for news page to show "read more" correctly.

...Read More

News

Message from the CEO - May 2018
09/05/2018

Welcome to the May 2018 investor update. The last quarter has seen good progress towards achieving several important milestones that are key...Read More

ASX:SDX Announcement

Appendix 4C - Quarterly Cash Flow Report - March 2018
30/04/2018

Sienna is pleased to release its Appendix 4C – Quarterly Cash Flow Report for the quarter ending 31 March 2018.

The Company ended the quarter with...Read More

ASX:SDX Announcement

Sienna Cancer Diagnostics Appoints Helen Fisher to Board
26/03/2018

Sienna is pleased to announce the appointment of Helen Fisher as an Independent Non-Executive Director and Chair of the Audit and Risk Committee effective ...Read More

ASX:SDX Announcement

Johns Hopkins Present Positive Study Results For Sienna’s hTERT Test
17/03/2018
    • 500 patient study confirms clinical utility of hTERT testing as an adjunct to...Read More

ASX:SDX Announcement

First IVD Product Sale in Switzerland
13/03/2018

Sienna is pleased to announce the first sale of the company’s hTERT test in Switzerland through its distribution partner, Biosystems Switzerland AG. ...Read More

ASX:SDX Announcement

Statlab Confident in Growth Trajectory of Sienna's hTERT Test in USA
19/02/2018

Sienna is delighted to provide shareholders with a video interview with Dan Eckert, CEO of StatLab Medical Products, Sienna’s exclusive US distributor.  ...Read More

News

Market Introduction For Sienna’s hTERT IVD Test in Denmark
15/02/2018
    • New test well received by pathologists across Denmark
    • ...Read More

ASX:SDX Announcement

Appendix 4D & Half Year Financial Report - Dec 2017
31/01/2018

The complete Appendix 4D and Half Year Financial Report for quarter ending 31 December 2017, can be found on the ASX announcements page:

Read More

ASX:SDX Announcement

Appendix 4C - Quarterly Cash Flow Report - Dec 2017
31/01/2018
The complete Appendix 4C for the quarter ending 31 December 2017, can be found on the ASX announcements page:https://www.asx.com.au/asxpdf/20180131/pdf/43r6p3q15b6pw2.pdf
Read More

Investor Update

Investor Update December 2017
06/12/2017

Please do not delete this line. It is required for news page to show "read more" correctly.

...Read More

News

Message from the CEO
05/12/2017

Welcome to the first Sienna Cancer Diagnostics investor update since our listing in August. We will provide updates when applicable to keep...Read More

News

The Bladder Cancer Diagnostic Market
05/12/2017
The first application of Sienna’s IVD test is as an adjunct to urine cytology to assist in the diagnosis of bladder cancer....Read More

News

What We Do And Why We Exist
05/12/2017
We are a medical technology company that develops and commercialises novel diagnostic tests for the pathology market. The first product launched by Sienna ...Read More

News

StatLab Distribution
05/12/2017
In order to gain the fastest possible sales traction in the US market and minimise direct costs, it was determined that a...Read More

News

Q&A with Mark Rees, PhD, VP of Advanced Diagnostics, StatLab Medical Products
05/12/2017
Dr Mark Rees has served as Vice President Advanced Diagnostics at StatLab since January 2014. Mark’s current...Read More

News

Sienna Teams Up With UoM to Provide Future Innovators Hands-on Experience
05/12/2017
We are passionate about our work at Sienna and actively engage in the development of young people seeking to establish careers in...Read More

News

IIR research report puts 31 cent target on Sienna
05/12/2017

Last month, Independent Investment Research (IIR) initiated coverage on Sienna. The report recognises Sienna as the first company to develop an IVD...Read More

ASX:SDX Announcement

Johns Hopkins Hospital Study Data To Be Presented At USCAP 2018
08/11/2017

An abstract discussing the results of a study performed by researchers at Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States ...Read More

ASX:SDX Announcement

Appendix 4C – Quarterly Cash Flow Report
18/10/2017

The cash balance at 30 September was $4.1 million, with net cash inflow for the quarter totalling $3.4 million. New capital issued through the Company’s ...Read More

ASX:SDX Announcement

Exclusive Distributor Appointed for Denmark and Sweden
25/09/2017

Melbourne, Australia, 25 September 2017: Sienna Cancer Diagnostics, a commercial stage, medical technology company focussed on the development and commercialisation of innovative cancer-related tests, is...Read More

ASX:SDX Announcement

Appendix 4E & 2017 Financial Report Release
31/08/2017

Sienna has released its Appendix 4E and Financial Report for the period ended 30 June 2017. These are the first financial results published by the...Read More

News

Sienna Cancer Diagnostics (ASX:SDX) Lists On ASX
03/08/2017

Highlights:

  • Sienna Cancer Diagnostics has listed on the Australian Securities Exchange (ASX) under the ticker code SDX
  • Sienna...Read More

News

Sienna Raises $4.6m From IPO
31/07/2017

Highlights:

  • Sienna raised $4.6 million, adding approximately 470 new shareholders to the Company’s share register
  • Sienna is the...Read More

News

Sienna IPO Closing July 17th
11/07/2017
Sienna’s Initial Public Offering (IPO) to raise up to $6M through the issuance of up to 30 million ordinary shares at an issue price of 20 cents each, will be coming...Read More

News

Sienna Seeks Listing on ASX with IPO
08/06/2017

Sienna has applied to the ASX for listing on the Australian Stock Exchange.

The company plans to issue up to 30,000,000 fully...Read More

News

Resources Added to Drive Key Strategies
04/05/2017
Sienna has added two key resources to the business to enable planning and execution of key strategies.

In the USA, Michael Gunderson has started...Read More

News

New CEO Appointed From Within Sienna
19/04/2017
Sienna Cancer Diagnostics Ltd today announced the Board’s decision to appoint Matthew Hoskin to the position of Chief Executive Officer (CEO). Matthew has served as...Read More

News

Successful Capital Raise Completed
03/03/2017

The Board and management of Sienna are pleased to announce the company has raised approximately $1.2 million as a result of recent capital raising activities....Read More

News

TGA Lists Sienna's IVD Product For Sale in Australia
14/12/2016
Sienna has completed its third major regulatory milestone for the quarter, receiving Therapeutic Goods Administration (TGA) listing on the Australian Register of Therapeutic Goods (ARTG)...Read More

News

Sienna Registers CE Marked IVD Product in EU
12/12/2016
Following on from their recent registration with the FDA in the United States, Sienna has now registered their CE-marked in-vitro diagnostic (IVD) medical device (to...Read More

News

Sienna Appoints Swiss Distribution Partner
08/12/2016
Sienna Cancer Diagnostics Ltd. and Biosystems Switzerland AG have entered an exclusive distribution agreement for the supply of Sienna’s IVD-registered Anti-hTERT Antibody (SCD-A7) throughout Switzerland.Read More

News

FDA Registration For Sienna - First IVD Product Listing
15/11/2016
Sienna Cancer Diagnostics has listed an in-vitro diagnostic (IVD) medical device with the United States Food & Drug Administration (FDA), achieving the final regulatory step...Read More

News

Sienna Receives ISO13485 Certification
14/10/2016

Sienna have received formal certification that their Quality Management System complies with the requirements of ISO13485.

ISO 13485 is the best internationally-accepted model a medical device...Read More

News

Sienna Receives $638K in R&D Tax Incentive Funding
13/10/2016
Sienna today reported the receipt of $637,524 from the R & D Tax Incentive program for the 2016 financial year.  During this time Sienna’s R&D...Read More

News

USA Distribution Partner Appointed
26/09/2016
Sienna is pleased to announce that leading specialty pathology supply company, StatLab Medical Products, will distribute Sienna’s telomerase detection assay to pathology laboratories across the...Read More

News

Sienna Enters Agreement With UK Distribution Partner
17/09/2016

Siena Cancer Diagnostics is pleased to announce the signing of an agreement with HistoCyte Laboratories for distribution of its In Vitro Diagnostic (IVD)...Read More

News

Sienna Files Additional Patent Application
18/08/2016

Sienna is pleased to announce the completion of a further patent application via the Patent Cooperation Treaty (PCT). The PCT process provides an efficient and...Read More

News

Sienna Announces Changes To Management Team
05/08/2016
  • Dr Cliff Holloway to stand down as CEO and Managing Director
  • Mr Carl Stubbings appointed Interim CEO
Sienna Cancer...Read More

News

University of Manchester to Conduct Health Economic Study
20/07/2016
A team of pathology and health economics experts at the Manchester Molecular Pathology Innovation Centre at the University of Manchester (MMPathIC), UK, have begun work...Read More

News

Johns Hopkins University Begin Follow-On Study
08/07/2016
Researchers at the Johns Hopkins University School of Medicine have begun work on a 1000 patient study to further demonstrate the clinical utility of Sienna’s...Read More

News

Appointment of Authorised Representative for EU
30/06/2016

In preparation for the registration of their first CE-marked IVD product in the European Union, Sienna has appointed an Authorised Representative for that region.

Bioconnexions Consulting...Read More

News

Sienna Raises $950K In New Capital
13/04/2016
Sienna Cancer Diagnostics Limited is pleased to announce that it recently raised approximately $950,000 in new capital. The funds were raised through the exercise of...Read More

News

Clinical Applications Manager Added To Sienna Team
07/04/2016

Sienna has appointed Shannon Turnbull as Clinical Applications Manager. Shannon has significant experience in Research & Development and commercialisation of clinical reagents for the clinical pathology...Read More

News

Johns Hopkins Researchers Present At USCAP
01/04/2016

Researchers from Johns Hopkins University School of Medicine recently presented a poster outlining the results from a study demonstrating the utility of Sienna’s telomerase assay as...Read More

News

Dr Donald Robertson Resigns from Board of Directors
31/03/2016

Sienna Cancer Diagnostics Ltd announces the resignation of Dr Donald Robertson from the Board.  Dr Robertson is the longest serving member of the...Read More

News

Sienna Appoints Dr John Chiplin Non-Executive Director
22/01/2016

Sienna Cancer Diagnostics Ltd is pleased to announce the appointment of Dr John Chiplin to the Board of Directors. 

Dr Chiplin is a very experienced healthcare...Read More

News

Sienna Receives R&D Tax Refund
19/01/2016

Sienna Cancer Diagnostics Ltd today announced it has received a $682,921 Research & Development (R&D) Tax Incentive refund for the 2015 financial year.  The R&D...Read More

News

Johns Hopkins abstract accepted for presentation at USCAP
20/11/2015

In March 2016, researchers from the Johns Hopkins Hospital will present results of a study examining the clinical utility of Sienna’s Anti-hTERT antibody (SCD-A7).

The study,...Read More

News

Sienna Announces Research Collaboration with Princess Alexandra Hospital and Pathology Queensland
28/10/2015

In an expansion of their global network of scientific and clinical research partners, Sienna Cancer Diagnostics has entered a research collaboration with the Princess Alexandra...Read More

News

Sienna Strengthens its Patent Portfolio
20/08/2015

Marking a significant milestone in its commercial growth strategy, Sienna Cancer Diagnostics has added to its intellectual property portfolio for telomerase assay technology, by filing...Read More

News

Dr Holloway Now Permanent CEO
26/06/2015

The Sienna board is pleased to announce that Cliff Holloway PhD has accepted the role of permanent Sienna CEO.

Dr Holloway was care-taking the role for...Read More

News

Sienna Enters Research Collaboration With UCLA
09/06/2015
In an expansion of their global network of scientific and clinical research partners, Sienna Cancer Diagnostics has entered a research collaboration with the prestigious UCLA,...Read More

News

Team Expansion
20/05/2015
In April and May, Sienna expanded its team to add further capability and capacity to drive key initiatives.

Deni Pisani, an experienced QA Manager,...Read More

News

Dr Cliff Holloway Appointed Interim CEO
04/02/2015
Sienna today announced that Dr Cliff Holloway has been appointed interim Chief Executive Officer. Dr Holloway will replace Dr Kerry Hegarty and commence work on...Read More

News

First Product Launch
18/01/2015

January 2015 – Marking one of the chief milestones of the Company since inception, Sienna is delighted to announce its agreement with the leading US...Read More

News

Sienna – On The Move !
15/12/2014
Sienna has recently completed a move from the Bio21 building in Parkville which was our home for the past 6 years, to a state of...Read More

News

Sienna Appoints CFO
28/11/2014
In November 2014, Sienna made its second senior management appointment during a very productive year. Sienna warmly welcomes Mr. Tony Di Pietro to the team...Read More

News

Sienna Raises $2.1M
31/10/2014

Sienna has just completed a $2.1M capital raising through a combination of the exercise of share options, plus the issue of additional shares.

These funds will...Read More

News

Sienna Lists First ASR Product With FDA
01/07/2014

In May 2014 Sienna Cancer Diagnostics announced the successful listing of its lead product, Anti-hTERT antibody (SCD-A7), with the US Food and Drug Administration (FDA)...Read More

News

Sienna Appoints Inaugural COO
23/02/2014

Sienna adds talent and capacity in inaugural COO role

  • Appointment of industry leader to emerging company
  • Growing team to...Read More

News

A$800,000 Grant For Commercialisation
01/02/2014

Cancer Diagnostics has been awarded a Federal Government grant to commercialise its innovative technology for use in a new, simple and cost-effective urine test for...Read More

News

Product Manufacture Begins
04/10/2013
Sienna has commenced regulatory compliant manufacturing of an analyte specific reagent that binds to telomerase. The manufacturing, performed under Good Manufacturing Practice (GMP), has been...Read More

News

Grant Funding
01/07/2013
Sienna has recently applied for funding as part of the federal government’s Early Stage Commercialisation grants, managed by Commercialisation Australia (CA). CA and its advisors...Read More

Sign up for updates